Abstract. Approximately 30% of chronic myeloid leukemia patients show initially no response to Imatinib, a potent inhibitor of BCR-ABL. This intrinsic resistance may be due to BCR-ABL-independent cell growth. Here we analysed the cytogenetic anomalies and the proteomic profiling in KCL22-S and KCL22-R, two Imatinib-sensitive and -resistant derivative cell lines of KCL22. A tetrasomy 8 and a non-reciprocal translocation +der(6)t(6;13)(p11.1;q12) were found only in KCL22-R as new evolved anomalies. Chromosome der(6)t(6;13) showed four variants differing in the chromatin content of 13q14-13qter including the retinoblastoma gene. Due to these sub-clones, approximately 65-79% of the Imatinibtreated KCL22-R cells showed a disomy and 21-35% a monosomy for 13q14. Imatinib removal reduced the main clone to approximately 20% in the benefit of the monosomic sub-clones. This was accompanied by an increased apoptosis rate and was revertible by Imatinib re-treatment. This effect may be connected with genes located in 13q14-qter. Proteomic profiling of the cell lines performed with ProteinChip technology (SELDI) revealed several differentially expressed proteins (n=45). In summary, we demonstrate here the complex changes on the cytogenetic and proteomic level which could be caused by Imatinib and the resistance resulting from it.
Introduction
Imatinib (STI571, Gleevec ® ) is a relatively new type of anticancer medication that can effectively block the proliferation in chronic myeloid leukemia (CML). It acts by inhibiting the tyrosine kinase BCR-ABL, a characteristic feature of CML that results predominantly from a reciprocal chromosomal translocation t(9;22)(q34;q11) (1, 2) . The BCR-ABL gene encodes for a constitutively active tyrosine kinase which is involved in a multitude of signalling and survival pathways that result in enhanced proliferation, decreased apoptosis and reduced adhesion of tumor cells (3) (4) (5) .
Although Imatinib is a very potent drug for targeting patients in the chronic phase of the disease, the response rates decrease during disease progression (6) . This type of primary Imatinib resistance strictly differs from the druginduced acquired resistance. The latter is caused either by mutations in the ATP-binding site of BCR-ABL or by its overexpression (7) (8) (9) . Patients showing acquired resistance respond initially to Imatinib but relapse within 12 months. Primary resistance to Imatinib, on the other hand, is observed in 20-30% of newly diagnosed patients (5) and in 22-50% of patients in accelerated or blastic phase (10) . It is characterised by a proliferation of tumor cells independent of BCR-ABL activity. However, what substitutes BCR-ABL function in those Imatinib-resistant cells is not well understood.
Surprisingly, the role of chromosomal changes has not been investigated in the context of primary Imatinib resistance to date albeit chromosomal changes and clonal evolution are clearly associated with disease progression in CML (11) . Approximately 71% of patients with CML in blast crisis show chromosomal changes in addition to t (9;22) . The most frequent secondary aberrations are gains of the Philadelphia chromosome, chromosomes 1, 2, 6, 7, 8 16, 17, 19 or 21 as well as a loss of chromosomes 3, 5, 7, 17 or 19 (12) . Chromosomal changes have also been shown to develop from Imatinib therapy. These aberrations affect neither additional chromosomes nor do they result in a new Imatinib-resistant clone (13) . So far no relationship between additional chromosomal changes and Imatinib resistance could be conclusively deduced.
ProteinChip technology (SELDI; surface-enhanced laser desorption/ionization) is a proteomic high-throughput technique that uses chromatographic surfaces able to retain proteins depending on their physico-chemical properties followed by direct analysis via time of flight mass spectrometry (TOF-MS) (14) . A multitude of studies using the ProteinChip technology were carried out for protein profiling of cells and body fluids (15) (16) (17) (18) (19) (20) (21) (22) .
In the present study we used cytogenetic analysis to characterise the Imatinib-sensitive and -resistant CML cell lines KCL22-S and -R to discriminate for numerical and structural chromosome aberrations and proteomic profiling to find differentially expressed proteins. Accordingly, we have identified characteristic chromosomal aberrations in the resistant cells and 45 differentially expressed proteins. These results provide in vitro evidence that Imatinib has an influence on specific chromosome aberrations and thereby causes several alterations in the proteome which may lead conclusively to resistance.
Materials and methods
Cell lines and cell proliferation/apoptosis analysis. The Imatinib-resistant cell line KCL22-R and its sensitive counterpart KCL22-S were established by Mahon and co-workers (23) to analyse primary Imatinib resistance in vitro. The parental cell line KCL22 is initially resistant to Imatinib (23) and consists of sensitive and resistant subpopulations, which can be isolated from the original cell line using methylcellulose. The KCL22-R cells employed in this study neither bear mutations in the ATP-binding site of BCR-ABL nor show BCR-ABL overexpression (23) . Therefore, they represent an adequate in vitro system to analyse Imatinib resistance which is based on a BCR-ABL-independent growth capacity. Cells were cultured in RPMI (Pan Biotech GmbH) with 10% FCS (Biochrom) in a 5% CO 2 atmosphere at 37˚C and were passaged twice weekly. The Imatinib-resistant cell line KCL22-R1 + was grown in the presence of 1 μM Imatinib. The tyrosine kinase inhibitor Imatinib, kindly provided by Andrea Uecker (Molecular Cell Biology department, FSU Jena), was prepared in sterile DMSO as a 10 mM stock solution and diluted to a working concentration of 100 μM with sterile PBS. We established a non-treated resistant clone from KCL22-R1 + by growing cells for three to six months without Imatinib (KCL22-R1 -). These cells were used to analyse changes associated with Imatinib therapy.
For proliferation assays, cells were seeded at a concentration of 1x10 5 cells per ml. Counting of cells was performed every 24 h using a Neubauer counting grid. Cells were stained with 0.5% Trypan Blue solution and vital cells were counted after 5 min at 37˚C. The growth rate was defined as the average of the percentage increase of cell number over the five days of culturing.
Apoptosis was examined with the Apo-ONE ® homogeneous caspase-3/7 assay kit (Promega) after 20 h of treatment with Imatinib or vehicle. Cells were harvested by centrifugation and resuspended in 100 μl PBS. The suspension (20 μl) was mixed with 20 μl Apo-ONE Assay solution and incubated for 2-4 h in the dark. Fluorescence was measured with a SpectraMAX Gemini spectrometer (Molecular Devices).
Cytogenetics and FISH.
Chromosome preparations and GTGbanding analysis were performed according to standard protocols (24) . Analysis of approximately 10 metaphases was carried out using an Axioplan 2 microscope (Zeiss, Germany).
Multiplex-FISH (M-FISH) was performed to confirm GTG-results as described by Weise and co-workers (25) . Ten metaphase images per cell line were captured on a fluorescence microscope (Axioplan 2, Zeiss, Germany) with a PCO VC45 CCD camera (PCO, Kehl, Germany) and suitable filter combinations (DAPI/FITC/Spectrum Orange/Texas Red/ Cyanine 5/Cyanine 5.5) using ISIS3-software (MetaSystems, Altlussheim, Germany). 24-Color-FISH using all 24 human whole chromosome painting probes was applied to identify interchromosomal rearrangements (25) .
To quantify relevant M-FISH data, interphase nuclei were hybridised with the centromere probe cep 6 (Spectrum Green), cep8 (Spectrum Green or Spectrum Aqua) and a retinoblastoma (Rb) gene (13q14.3) locus specific probe LSI 13S319 (Spectrum Orange) (Abbott) as previously described (24) . Signals of 200-250 interphase nuclei were analysed. The 'cut-off' for trisomy/tetrasomy 8 and monosomy 13q14 was 4% and 8%, respectively according to lab standards based on the analysis of 200-250 cells. BCR-ABL breakpoint was confirmed using LSI Dual Color Dual Fusion probe (Abbott) and by PCR using oligonucleotides as described (26) .
High resolution multi-color banding (MCB) was performed to analyse the breakpoints in chromosome der(6)t(6;13)(q11.1;q12). Overlapping microdissected labelled probe sets were hybridised on metaphase spreads as described previously (27) .
ProteinChip Array analysis. Cells were lysed with 9.5 M urea, 2% CHAPS, 1% DTT for 15 min at RT and centrifuged at 12000 x g for 15 min. Protein concentration of supernatants was measured by the Bradford method. Equal amounts of protein (30-50 mg/ml) in a total volume of 50-100 μl lysate were applied to the fractionation using QHyperD columns (Ciphergen) according to the manufacturer's guidelines. Whole cell lysates and fractionated samples were analyzed on IMAC Cu(II) protein arrays (Ciphergen Biosystems Inc, Fremont, CA) as described elsewhere (28) . Mass analysis was performed in a ProteinChip Reader (series 4000, Ciphergen Biosystems Inc) according to an automated data collection protocol. After normalization based on total ion current and calibration of data, peaks with a signal-to-noise ratio of 10 were combined as clusters, using the CiphergenExpress 3.0 program (Ciphergen Biosystems). The p values were calculated by nonparametric Mann-Whitney U test (two-way comparisons), using the CiphergenExpress 3.0 program. Protein peaks with p values <0.05 were considered significantly deregulated (up-regulated or down-regulated) in lysates of KCL22-S and -R. Up to ten biological replicates were analysed using the described procedure.
Results
The effect of Imatinib on cell growth and apoptosis in KCL22-S and KCL22-R. Cell proliferation was significantly reduced in the presence of 1 μM Imatinib in both, the sensitive cell line KCL22-S and the parental cell line KCL22-P. In contrast, the resistant cell line KCL22-R exhibited an elevated growth rate in the presence of Imatinib (data not shown).
Apoptosis in KCL22-S was significantly increased (47%) after treatment with 1 μM Imatinib for one day (Fig. 1) . In contrast, Imatinib caused no significant effect on the apoptosis rate in KCL22-R. Contrarily, Imatinib even decreases caspase activity by approximately 8% in KCL22-R.
Karyotype analysis by GTG-banding and M-FISH.
Ten metaphases of individual clones of each, the sensitive (KCL22-S1, KCL22-S2), the resistant (KCL22-R1 + and KCL22-R2 + ), the parental KCL22-P, and the Imatinib-deprived resistant KCL22-R1 -cell lines, were analysed by GTG-banding and M-FISH. The composite karyotype of the parental cell line KCL22-P was 47~50,X,del(X)(p),+der(1)t(1;10)(p13;?), +6,+8x2,der(9)t(9;22)(q34;q11),der(17)t(17;19),i(21)(11.1), der(22)t(9;22)(q34;q11)x2[cp10]. These aberrations are in line with previously published data (29) . However, we were able to obtain a more detailed characterization of these aberrations due to FISH analysis. The breakpoint in chromosome 1 was allocated to p13 and the described loss of chromosome X was restricted to Xp. KCL22-S and -R showed almost all of these aberrations ( Fig. 2A and B) . However, KCL22-S and KCL22-R showed an additional translocation t(8;21)(p21?;?) that was not present in the parental cell line. A non-reciprocal translocation +der(6)t(6;13)(p11.1;q12) was exclusively found in KCL22-R. The extent of the translocated material of chromosome 13 was different in individual metaphases resulting in smaller or larger chromosomes der(6)t(6;13) The sensitive cells showed also a gain of chromosome 6 but without t(6;13). A loss of one chromosome 13 was an additional characteristic feature of one KCL22-R clone.
Variants of chromosome der(6)t(6;13) in KCL22-R. Multicolor banding (MCB) was performed to map the breakpoints of the translocation t(6;13)(p11.1;q12) in KCL22-R in more detail.
The breakpoints in t(6;13) were assigned to 6p11.1 and 13q12 (Fig. 3) . However, the portions of the translocated material of 13q varied in individual clones extending from 13q12 to different distal positions (Fig. 4) . Approximately 25% of the metaphases showed a derivative chromosome 6 with a complex translocation t(3;13;6)(?;p12;p11.1) while the breakpoints on chromosomes 6 and 13 were identical to those in der(6)t(6;13). Taken together translocation t(6;13) resulted in a loss of trisomy for 6p10_pter, a monosomy for 13q10_q11, and in sub-clones with variable portions of 13q12_qter. (1) and in 18% of KCL22-R cells. In contrast, the predominant subpopulation with a share of 80% showed a tetrasomy 8 in KCL22-R which occurred in <5% of KCL22-S cells. Interphase FISH employing a locus specific probe for 13q14 showed a normal FISH signal pattern for the KCL22-S cells. The KCL22-R cell line exhibited a monosomy for 13q14 in 22% and a disomy in 78% as detected in interphase FISH analysis (Fig. 6 ). This cell population is constituted by one or two sub-clones (sub-clone E and probably also D, see Fig. 4 ) lacking 13q14_qter in chromosome der(6)t(6;13)(p11.1;q12). This was confirmed by FISH on metaphase spreads providing the two types of derivative chromosome der(6) (Fig. 5) .
Subclones of KCL22-S and KCL22-R.

Influence of Imatinib treatment on the size of sub-clone with monosomy 13q14.
We observed an increased cell growth in KCL22-R with Imatinib compared to without. Therefore we Figure 3 . Multi-color banding (MCB) analysis for chromosome 6 refining the breakpoints in chromosome der(6)t(6;13). From left to right: inverted DAPI; pseudo-color image; fluorescence channels, FITC, Spectrum Orange, Texas Red, Cy5 and DEAC. A normal chromosome 6 (A) and chromosome der(6)t(6;13) (B). The breakpoint was mapped to 6p11.1. Figure 4 . MCB of chromosome 13 refining the breakpoints in chromosome der(6)t(6;13). From left to right: inverted DAPI; pseudo-color image; fluorescence channels, FITC, Spectrum Orange, Texas Red, Cy5 and DEAC. A normal chromosome 13 (A) and chromosome der(6)t(6;13) (B-F). The breakpoint was mapped to 13q12. Five sub-clones with varying chromatin content from 13q14_qter: (B) der(6)t(6;13)(6qter_6p11.1::13q12_13qter), (C) der(6)t(6;13)(6qter_6p11.1::13q12_13q22), (D) der(6)t(6;13) (6qter_6p11.1::13q12_13q14), (E) der(6)t(6;13)(6qter_6p11.1::13q12_13q13) and (F) der(6)t(3;13;6)(6qter_6p11.1::13q12_13q14::3?). . FISH pattern with centromer probes for chromosome 6 (Spectrum Green) and LSI 13 (Spectrum Orange) demonstrating a disomy for 13q14 (A) and a monosomy for 13q14 (B) resulting from a loss of the target sequence in chromosome der(6)t(6;13)(p11.1;q12) (arrow).
questioned whether this could result from different growth properties of the different sub-clones in KCL22-R. Interestingly, withdrawal of Imatinib reduced the clone size of the cells with a disomy for 13q14 in favour of the monosomic cells from 64% to 16% within two weeks (KCL22-R -; Fig. 7) . A proportion of the monosomic cells remained stable at approximately 21% in a follow-up of three months (Fig. 6) . Vice versa, re-treatment of KCL22-R -with Imatinib restored the initial proportion of the disomic cells in favour of the monosomic cell population. The latter is shown in Fig. 7 by a deferred increase of disomic cell population to approximately 62% within 2-3 weeks.
ProteinChip (SELDI) profiling. Analysis of fractionated cell lysates revealed 45 differentially expressed proteins, 31 peaks were found overexpressed in the resistant cell line while 14 peaks were characteristic markers for the sensitive cell line ( Table I ). The majority of expression differences was found in the pH 9.0 fraction. For example, as shown in the cluster blot analysis (Fig. 8A ) the peak with the molecular mass of 5468 Da showed an 8-fold overexpression in the sensitive cell line (median intensity, 129) compared to the resistant cell line (median intensity, 16) with a p value of 0.00071. The ROC curve analysis showed an area under curve (AUC) of 0.91. The 7482-Da peak was 6-fold overexpressed in the resistant cell line (median intensity 31 to 5, Fig. 8B ) with an AUC of 0.89 and a p value of 0.00091. A representative SELDI spectra for these two peaks is depicted in Fig. 9 .
Discussion
Cytogenetic and proteomic analysis of KCL22-R and KCL22-S has revealed common and discriminating aberrations between both cell lines. With cytogenetic analysis a tetrasomy 8 and a translocation t(6;13) are found to be characteristic for KCL22-R and absent in KCL22-S. These additional chromosomal anomalies in KCL22-R might result from the continuous exposure to Imatinib as the observed gain of chromosome anomalies in Imatinib-treated patients (13) . The increment of chromosome aberrations is probably raised by the repressed wild-type ABL-kinase, an essential regulator of RAD51 that is known to promote DNA repair (30, 31) . The tetrasomy 8 was found in >80% of the KCL22-R cells but in <5% of KCL22-S (Fig. 6) . Gain of chromosome 8 is one of the most frequent aberrations occurring in 34% in CML during disease progression (32) . Among the numerous genes on chromosome 8 MAPKs, PTK2B, and the oncogene c-myc are the most prominent and potential players contributing to the BCR-ABLindependent growth control in KCL22-R. These putative candidates have not been analysed in the gene expression analysis of Tipping and co-workers (33) . Therefore it remains open whether KCL22-R overexpresses these genes. However, since KCL22-S presented a trisomy-8, it seems unlikely that the tetrasomy-8 in KCL22-R will contribute significantly to the BCR-ABL-independent cell growth. The breakpoints of the second characteristic aberration of KCL22-R the translocation t(6;13), were mapped to (p11.1;p12) by multi-color banding. This aberration was not detected in KCL22-S nor in the parental cell line KCL22 which show an intermediate resistance against Imatinib compared to KCL22-R and KCL22-S (data not shown). This demands a more accurate mapping of the translocation breakpoint to detect potentially affected genes that contribute to the BCR-ABL-independent phenotype.
Noteworthily, chromosome der(6)t(6;13) showed a remarkable variability. This is documented by five variant clones with variable amounts of chromatin from 13q13 to 13qter within the der(6)t(6;13) chromosome (Fig. 4) . From the evolutionary point of view, this variation is expected to correlate with distinct growth properties. Effectively, Imatinib treatment was capable of modulating the clone size of the cells with different variants of the aberrant chromosome 6. In permanent Imatinib-treated KCL22-R (KCL22-R + ) we identified a disomy for 13q14 in the main cell population (65%). Interestingly, withdrawal of Imatinib reduced the number of 13q14 disomic cells in benefit of the 13q14 monosomic cells from 65% to 16% within two weeks as shown in Fig. 7 (KCL22-R  -) . Thus the 13q14-qter disomic sub-clones have a growth disadvantage versus the 13q14-qter monosomic sub-clones in Imatinib-deprived KCL22-R. Re-treatment of KCL22-R -with Imatinib restores the initial clone size of the disomic cells and reduces the monosomic cell population (KCL22-R -+ ). It seems difficult to understand how the 13q14 monosomic, Imatinib-sensitive clone has evolved and is preserved in permanently Imatinib-treated KCL22-R. However, it is conceivable that loss of Imatinib stability before the next cell passage may give this clone sufficient time to 'catch up'. This explanation is supported by the rapid and dramatic clone expansion that we observed in Imatinib-deprived and retreated KCL22-R.
We have shown that Imatinib has a positive effect on cell growth of KCL22-R. From this we conclude that active BCR-ABL or other Imatinib-sensitive kinases act negatively on cell proliferation. The data described above indicate that this effect is restricted to some KCL22-R sub-clones. This also explains the attenuated cell growth and increased apoptosis rate of KCL22-R after Imatinib withdrawal. Similar results were reported for the cell lines BaF/BCR-ABL and LAMA84 where withdrawal of Imatinib induced apoptosis (34) .
Active BCR-ABL could induce apoptosis via JNK/SAPK after activation through Ras (35, 36) . It can be assumed that it also inhibits cell proliferation via the Rb gene as is observed for ABL (37) . Rb is localized in 13q14.3 and is therefore lost in the truncated der(6)t(6;13) that marks the predominant sub-clone of Imatinib-deprived KCL22-R cells. However, we have no evidence so far that loss of heterozygosity of Rb is causal for the distinct growth behaviour of the KCL22-R -subclones.
There are many other genes in 13q14_qter that could contribute to this different growth behaviour of the 13q14 disomic and monosomic sub-clones in KCL22-R. Considering the fact that Imatinib acts anti-apoptotically and promotes cell growth of BCR-ABL-independent CML clones, clinical application of Imatinib should be critically reconsidered in advanced disease stages.
The proteomic analysis of the two cell lines performed with ProteinChip Arrays revealed several differentially expressed proteins that could be linked to the described chromosomal changes. Forty-five proteins were found with significantly changed intensities in KCL22-S and -R. These proteins must be identified and could probably be assigned to the altered chromosomal regions described above. Whether these proteins can be linked to signal transduction pathways that play a role in the BCR-ABL-independent growth of CML cells will be investigated further. This may reveal new targets for therapy of primary Imatinib-resistant CML patients. Table I . Differentially expressed protein peaks in KCL22-S and -R in fractionated samples.
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